Powered by

Intec Pharma Advances Medical Cannabinoid Development Program With Dosing of First Patient in a Phase 1 Pharmacokinetic Study of Accordion Pill-THC

Jan 02, 2019 - PR Newswire

PR Newswire

Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill(TM) platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis.

The Phase 1 PK study is a single-center, single-dose, randomized, open-label three-way crossover study to investigate the PK, safety and tolerability of AP-THC in up to...